

E *T* *E*

FGG

B. Basis for determining the Participants and the scope of the Participants

(1) Basis for determining the Participants

As of the end of the reporting period, the Company has established a research and development department, which is responsible for the research and development of new products. The research and development department is currently in the process of developing a new product, which is expected to be launched in the near future. The research and development department has a total of 10 employees, including 5 research and development personnel, 3 administrative personnel, and 2 support personnel. The research and development department has a total of 10 employees, including 5 research and development personnel, 3 administrative personnel, and 2 support personnel.

(2) Scope of Participants

The Company's research and development department has a total of 10 employees, including 5 research and development personnel, 3 administrative personnel, and 2 support personnel. The research and development department has a total of 10 employees, including 5 research and development personnel, 3 administrative personnel, and 2 support personnel. The research and development department has a total of 10 employees, including 5 research and development personnel, 3 administrative personnel, and 2 support personnel.

The Company's research and development department has a total of 10 employees, including 5 research and development personnel, 3 administrative personnel, and 2 support personnel. The research and development department has a total of 10 employees, including 5 research and development personnel, 3 administrative personnel, and 2 support personnel. The research and development department has a total of 10 employees, including 5 research and development personnel, 3 administrative personnel, and 2 support personnel.

The Company's research and development department has a total of 10 employees, including 5 research and development personnel, 3 administrative personnel, and 2 support personnel. The research and development department has a total of 10 employees, including 5 research and development personnel, 3 administrative personnel, and 2 support personnel. The research and development department has a total of 10 employees, including 5 research and development personnel, 3 administrative personnel, and 2 support personnel.

(3) Circumstances for ineligibility of the Participants of the Scheme

- ()
- ()
- ()
- ()
- ()
- ()

C. Source and number of shares under the Scheme

(1) Source of shares of the Scheme

T
A

(2) Total number of the Share Options involved in the Scheme

The chart displays the following data points:

Category	Value	Percentage
(First Grant of Share Options–),	5,947,858	0.28%
(Reserved Share Options–),	2,146,893,254	0.25%
(First Grant of Share Options–),	5,353,072	90%
(Reserved Share Options–),	2,146,893,254	0.03%
(First Grant of Share Options–),	594,786	10%

(2) Date of Grant

A
60
60
T
A
60
T
12
T
E

(3) Vesting Period

A
T
12
E

(4) The Exercise Date

T
T
E
E

T		:	
		Proportion of exercisable Share Options to the total number of Share Options granted	
Exercise Arrangement	Exercise Period		
E	12	20%	
	24		
E	24	20%	
	36		
T E	36	20%	
	48		
E	48	20%	
	60		
E	60	20%	
	72		
E			
A	E		

(5) Lock-up Period

T
A
A

:

()
25%

()

()
A
A
E

E. Exercise Price and basis of determination of the Scheme

E
A
E

()

() , , , .

(2) Exercise Conditions of the Share Options

[illegible]

() T

() , ;

()

()

A A ; 36

[illegible]

() , , , .

()

() T

()
 12 ;

()

()

Exercise Period

Targets of Performance Assessment

[illegible]

()

T

A

T

2021

(3) Description of scientificity and reasonability in the setting of performance assessment indicators by the Company

T

E

A

A

2020,

() 25.1 () T 0.019 T -0

()

$$= 0 \times (1 + 2 \times) / 1 \times (1 +)$$

: 0 E ; 1 ; 2
 (.) ;
); E

()

$$= 0 \div$$

: 0 E ; E

()

$$= 0 \cdot \boxtimes$$

: 0 E ; $\boxtimes$
 A E
 ,

()

E

(3) Procedures for adjustment of the Scheme

T , E
 . T
 E
 . T
 A A

H. Procedures for implementation of, Grant of, exercise of and amendments to and termination of the Scheme

(1) *Procedures for the Scheme to take effect*

- () T () E A 2021
- () T () A 2021 E
- () T
- () T
- () T () 2 ()
- () T 6
- () 10 T T 5

() T
 ,
 A

() T
 . A
 . T
 60 (60)
 3

()
 12
 12

(3) *Procedures for the exercise of the Share Options*

() T
 E
 E
 E
 A
 E
 T
 A

()
 A

() A
 ()

- () A
- ()
- T

(4) Procedures for amendments to the Scheme

- E
- T
- T
- A
- A

(5) Procedures of termination of the Scheme

-
-
-

T
A
A

I. Rights and obligations of the Company and Participants

(1) *Rights and obligations of the Company*

() T
E

() T

() T

() T

() T

() T
 E
 T

()

(2) *Rights and obligations of the Participants*

() T

() T

()

() T
 T

() T


() T

()
 A 8 A

(1) Exercise Price under the First Grant of Share Options

(2) Basis of determination of the Exercise Price under the First Grant of Share Options

T E



B. Mechanism for occurrences of the Participants

(1) *Change of position of Participants*



(2) Resignation of the Participant

1. The participant has resigned from the study.

(3) Retirement of the Participant

1. The participant has retired from the study.

(4) Resignation of the Participant due to incapacity in working

() The participant has resigned from the study due to incapacity in working.

() The participant has resigned from the study due to incapacity in working.

(5) Death of Participants

() The participant has died.

()

(6) *Change to the control in the subsidiary where the Participant is working for*

1. *What is the purpose of the study?*
 2. *What are the research questions or hypotheses?*
 3. *What is the study design?*
 4. *What is the sample size and how was it selected?*
 5. *What are the variables being studied?*
 6. *What are the data collection methods?*
 7. *What are the results of the study?*
 8. *What are the conclusions of the study?*
 9. *What are the limitations of the study?*
 10. *What are the implications of the study?*

(7) *Change to eligibility of the Participant*

Figure 1. The effect of the number of trials on the number of correct responses. The number of correct responses was significantly higher than the number of incorrect responses in all cases. The number of correct responses was significantly higher than the number of incorrect responses in all cases. The number of correct responses was significantly higher than the number of incorrect responses in all cases.

() $12 \frac{1}{2}$;

()

12 ;

()

12

()

()

() , , , .

C. Other circumstances

1. The first step is to identify the **main idea** of the passage. This is usually found in the first sentence or paragraph.

4. ACCOUNTING TREATMENTS METHOD AND THE MEASUREMENT OF PERFORMANCE IMPACT

A. Accounting treatment method

(1) Date of Grant

the $\mathcal{H}^1$ -norm. The first term on the right-hand side of (2.10) is the $\mathcal{H}^1$ -norm of the function $\mathcal{H}^1(\mathbb{R}^d)$ and the second term is the $\mathcal{H}^1$ -norm of the function $\mathcal{H}^1(\mathbb{R}^d)$. The first term on the right-hand side of (2.10) is the $\mathcal{H}^1$ -norm of the function $\mathcal{H}^1(\mathbb{R}^d)$ and the second term is the $\mathcal{H}^1$ -norm of the function $\mathcal{H}^1(\mathbb{R}^d)$.

(2) Vesting Period

(3) Accounting treatment after the Exercise Date

1. *Chlorophyll a* (Chl *a*) and *Chlorophyll b* (Chl *b*) were determined using the method of Arar and Collins (1997). The concentration of Chl *a* and Chl *b* was expressed as $\mu\text{g mL}^{-1}$ of the sample.

(4) Exercise Date

The map shows the northern Adriatic coastline from Trieste in the north to the Gulf of Genoa in the south. Sampling stations are indicated by numbers 1 through 15. Station 1 is near Trieste, station 2 is further south, and stations 3 through 15 are distributed along the coast and in the open sea. The map includes latitude lines (45°N, 44°N, 43°N) and longitude lines (13°E, 12°E, 11°E, 10°E). A scale bar at the bottom indicates distances from 0 to 100 km.

(5) Fair value and determination of the Share Options

() : 42.89 (17 A, 2021)

- () : 1 , 2 , 3 , 4 5 , ()
- () : 14.73%, 17.44%, 18.71%, 17.92% 16.55% (, E)
- () : 1.50%, 2.10% 2.75% (- , -)

B. Expected impact of the implementation of Share Options on operating performance in each period

T 5,353,072

T

T 60,332,200

A

A 2021,

E

2021 2026

: 10'000

Amortized costs of the Share Options	2021	2022	2023	2024	2025	2026
6,033.22	826.72	2,180.92	1,405.03	910.43	517.12	193.00

1. T
- 2.
3. T
4. A 383 T ()T 0. 35

T

5. IMPLICATIONS UNDER THE LISTING RULES

T A

14A.92(3)()

17

14A

A

A

/

6. WAIVERS FROM STRICT COMPLIANCE WITH THE LISTING RULES

A

A

17

T

E

E

17.03

(1) Waiver from strict compliance with Note (1) to Rule 17.03(9) of the Listing Rules regarding the basis of determination of the Exercise Price

(1) 17.03(9)

()

()

A

()

A

A

()

A

20/60/120

A

E
 (1) 17.03(9)
 E
 A
 E

(2) Waiver from strict compliance with Rule 17.03(13) of the Listing Rules regarding the adjustment of Exercise Price in the event of dividend distribution

17.03(13)
 E
 17.03(13)
 E
 E
 E
 A
 0.28%
 A
 T
 0.25
 A
 A
 E
 5,947,858,
 0.35%
 ; ()
 ; ()
 A
 A
 A

7. THE SHAREHOLDERS' GENERAL MEETING

7. THE SHAREHOLDERS' GENERAL MEETING

DEFINITIONS

DEFINITIONS

A ()- () E (: 601865)

A (《上 公司股權激勵管理辦法》).

A A - ()- () E,

()- ()

()-

E -

E -

E -

E -

5,947,858

() -

()

0.25

E (: 6865)

A

() -

()

T E

() -

A

T

2021 A

A () ()

()—

()

()

E-

E

E

E

E

E

E

T

E

E

()—

()

W —

w



E

%—

Flat Glass Group Co., Ltd.
Ruan Hongliang

17 April 2021

A

 $a,$